Emeryville, Calif., February 20, 2009 – ADMEcell, Inc. today announced that it has entered into an exclusive agreement with Advancell, Barcelona, Spain, to manufacture and distribute the CacoReady™ System for the North American market.
The CacoReady™ System is a new, innovative tool designed to optimize the time and costs of evaluating the intestinal absorption of compounds. The kit has been designed to provide an off-the-shelf user-friendly stand alone kit as well as a solution suitable for high-throughput automated procedures. It provides users with the differentiated Caco-2 barrier (21-day system), plated on 24- or 96-Transwell plates.
“This kit with differentiated Caco-2 cell barriers (shipped at day 13 of differentiation) is an innovation that is being offered in North America for the first time,” says Sandy Koshkin, President of ADMEcell. “Our customers gain considerable savings of both cost and time.” The CacoReady product is shipped in proprietary shipping media at room temperature, and arrives ready for immediate use. About Advancell
Advancell Advancell (www.advancell.net) is a leader in nanomedicine and services and reagents in both ADME/Tox and Skin Biology areas, including cell-based assays. Advancell’s business model allows it to achieve substantial reductions in costs, risks and the development time of a drug. Their most successful product to date is the CacoReady™ System, which measures intestinal absorption of newly discovered drugs.
ADVANCELL operates throughout three divisions: Advancell Therapeutics, which concentrates its activity in development, through to clinical concept testing of innovative pharmaceuticals in the search for new applications for known molecules; Advancell Alternative Testing, which uses in-vitro methods to predict cell efficiency, security, and the mechanism of molecule development, and Advancell Nanosystems, which uses nano-medicine to treat and prevent illnesses. The company is headquartered in Barcelona and has three different research centres in Spain. About ADMEcell ADMEcell, Inc. is an on-demand supplier of cell-based assay kits servicing the biotech and life sciences industries. Located in Emeryville, California, the company manufactures and distributes innovative and leading edge products through licensing and distribution agreements. ADMEcell’s product offerings enable rapid, sophisticated cell-based assays designed for in vitro therapeutic modeling and re-profiling. The common theme among the selected technologies is their leading edge nature and prominence within a chosen market. www.admecell.com
Licensing and Distribution Opportunties:
ADMEcell is currently considering the licensing and/or distribution of unique, state-of-the-art cell-based assays that have important applications in the drug discovery process. We are located in the San Francisco bay area and are partnered closely with a cell culture manufacturer to produce products under GMP. Please contact (contact is email link: info@admecell.com ADMEcell in confidence if you have a unique, compelling cell-based assay that is relevant to the biotechnology and life science marketplace, particularly to ADME-toxicology. www.admecell.com(link)) Press Release / Story Admecell Enters into an Agreement to Exclusively Manufacture and Distribute Advancell’s CacoReady System Throughout North America URL www.admecell.com First Name Sandy Last Name Koshkin Email sandy@admecell.com
